Seeking Alpha
22 Jul 2026, 17:50 UTC · 56m ago
Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
22 Jul 2026, 17:50 UTC · 56m ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Fortress Biotech's market capitalization is currently trading below its cash balance of $255.8M. — Trading below cash value typically signals a deep-value opportunity or an undervalued asset floor for investors.
+0.80Fortress Biotech realized a net profit in Q1 2026 following the sale of the ZYCUBO PRV. — While positive for the balance sheet, the impact is moderated because the article identifies this as a one-off event.
+0.40Journey Medical, 36% owned by FBIO, is showing strong growth driven by Emrosi prescriptions. — Consistent commercial revenue growth from a subsidiary provides a fundamental tailwind for the parent company.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Company is described as offering deep value with a dramatic cash increase and net profit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Zacks Investment Research
2h ago
